Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease

    NEXT STORY
    Sugar Balance: Review PureHealth Research Diabetes Supplement
    PREV STORY
    Spring Bank Pharmaceuticals Announces Special Dividend of Contingent Value Rights
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    G1 Therapeutics Announces Pricing of Offering of Common Stock

    RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: ...

    author_avatar
    NASDAQ Market News

    BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

    author_avatar
    NASDAQ Market News

    Precision Therapeutics Announces Corporate Name Change To Predictive Oncology Inc.

    author_avatar
    NASDAQ Market News